Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Resectable Lung Non-Small Cell Carcinoma 1Nasopharyngeal Carcinoma 1Immunotherapy Esophagus Cancer 1Hepatic Artery Infusion 1Advanced Solid Tumor 1

Interventions

Injections 12pembrolizumab 7toripalimab 6tislelizumab 5Oxaliplatin 3Gemcitabine 3Cisplatin 3Carboplatin 3trastuzumab deruxtecan 2spartalizumab 2lenvatinib 2atezolizumab 2Paclitaxel 2Nivolumab 2Immune Checkpoint Inhibitors 2Fulvestrant 2Fluorouracil 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Bevacizumab 2Albumin-Bound Paclitaxel 2zimberelimab 1penpulimab 1olaparib 1niraparib 1nedaplatin 1fludarabine phosphate 1fludarabine 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Solid Tumor × nedaplatin × Clear all
NCT06953323 2026-03-27

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
86 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡